Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Trial details
- Registry ID
- NCT06697301
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.NCT06697301 | Eikon Therapeutics | Phase 2, Phase 3 | Recruiting | 2035-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |